Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer

Inclusion Criteria: * Have histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma based on pathology report with radiologically identified metastases that meet Response Evaluation Criteria in Solid Tumors (RECIST) criteria. * Be willing and able to provide written informed consent for the trial. * Have at least one measurable lesion by RECIST criteria. * Have had prior treatment with at least one line of therapy for metastatic disease. * Have had tumor mutation profiling from any Clinical Laboratory Improvement Act (CLIA) certified laboratory demonstrating a KRAS mutation. Liquid biopsy demonstrating KRAS mutation will be considered acceptable. * Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) performance scale. * Absolute neutrophil count (ANC) \>= 1500/uL (specimens must be collected within 10 days prior to the start of trial treatment). * Platelets \>= 100,000/uL (specimens must be collected within 10 days prior to the start of trial treatment). * Hemoglobin \>= 9.0 g/dL (specimens must be collected within 10 days prior to the start of trial treatment). * Creatinine OR measured or calculated creatinine clearance (glomerular filtration rate \[GFR\] can also be used in place of creatinine or creatinine clearance \[CrCl\]) =\< 1.5 x upper limit of normal (ULN) OR \>= 50 mL/min for subjects with creatinine level \> 1.5 x ULN (specimens must be collected within 10 days prior to the start of trial treatment). * Tota…